Most notably, of the twenty-nine adenocarcinomas, FGFR2 gene fusions were specifically enriched in cholangiolocarcinoma (CLC), with 79.3% (23/29) of cases displaying CLC. Here, FGFR2 is linked to adenocarcinoma.